Irinotecan and temozolomide brain distribution: A focus on ABCB1

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 1, 2014, Pages 185-193

  Goldwirt, Lauriane ^a   Beccaria, Kevin ^b   Carpentier, Alexandre ^b   Farinotti, Robert ^a   Fernandez, Christine ^a,c  

^a EA4123   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

ABCB1; Brain distribution; Glioblastoma; Irinotecan; SN 38; Temozolomide

Indexed keywords

FIRTECAN; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; MYLAN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; COMPARATIVE STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; FEMALE; GLIOBLASTOMA; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CAMPTOTHECIN; DACARBAZINE; FEMALE; HALF-LIFE; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; NERVE TISSUE PROTEINS; NEURONS; P-GLYCOPROTEINS; PRODRUGS; TISSUE DISTRIBUTION; TOPOISOMERASE I INHIBITORS;

EID: 84903816503     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2490-0     Document Type: Article

References (46)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncology 14(Suppl 5):v1-v49
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes A, Marosi C, Bogdahn U, Curschmann Jr, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996 (Pubitemid 40349501)
3. Denny BJ, Wheelhouse RT, Stevens MFG, Tsang LH, Slack JA (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33(31):9045-9051 (Pubitemid 24272851)
4. Potmesil M (1994) Camptothecins: from bench research to hospital wards. Cancer Res 54(6):1431-1439
5. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller L (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17(5):1516
6. Prados MD, Lamborn K, Yung WKA, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8(2):189-193 (Pubitemid 46542664)
7. Basili S, Moro S (2009) Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opin Ther Pat 19(5):555-574
8. Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, Verweij J (1998) Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 4(11):2747-2754 (Pubitemid 28523501)
9. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodbrain barrier sites. PNAS 86(2):695-698 (Pubitemid 19037807)
10. Jetté L, Murphy GF, Leclerc J-M, BÈliveau R (1995) Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol 50(10):1701-1709
11. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97(11):2517-2524 (Pubitemid 26187339)
12. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D (2009) A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 20(1):175-181
13. Goldwirt L, Zahr N, Farinotti R, Fernandez C (2013) Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study. Biomed Chromatogr 27(7):889-893
14. Goldwirt L, Lemaitre F, Zahr N, Farinotti R, Fernandez C (2012) A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10- hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics. J Pharm Biomed Anal 66:325-333
15. Atsumi R, Okazaki O, Hakusui H (1995) Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3′,4′:6,7]- indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats. Biol Pharm Bull 18(8):1114-1119
16. Kaneda N, Hosokawa Y, Yokokura T, Awazu S (1997) Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats. Biol Pharm Bull 20(9):992-996 (Pubitemid 27432874)
17. Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16(3):303-309
18. van Waterschoot RAB, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH (2010) Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int J Cancer 127(12):2959-2964
19. Gallo JM, Li S, Guo P, Reed K, Ma J (2003) The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 63(16):5114-5117 (Pubitemid 37022652)
20. Wang F, Zhou F, Kruh GD, Gallo JM (2010) Influence of bloodbrain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncology 12(10):1043-1049. doi: 10.1093/neuonc/noq056
21. Nakanishi H, Yonezawa A, Matsubara K, Yano I (2013) Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models. Eur J Pharmacol 710(1-3):20-28
22. Hirst TC, Vesterinen HM, Sena ES, Egan KJ, Macleod MR, Whittle IR (2013) Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? Br J Cancer 108(1):64-71
23. Mitchell RB, Dolan ME (1993) Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 32(1):59-63 (Pubitemid 23105008)
24. Patel M, McCully C, Godwin K, Balis FM (2003) Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61(3):203-207 (Pubitemid 36342297)
25. Reyderman L, Statkevich P, Thonoor CM, Patrick J, Batra VK, Wirth M (2004) Disposition and pharmacokinetics of temozolomide in rat. Xenobiotica 34(5):487-500 (Pubitemid 38901458)
26. Newlands E, Blackledge G, Slack J, Rustin G, Smith D, Stuart N, Quarterman C, Hoffman R, Stevens M, Brampton M et al (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65(2):287-291
27. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ (1997) Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3(7):1093-1100 (Pubitemid 27319755)
28. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81(6):1022-1030 (Pubitemid 29516147)
29. Darkes MM, Plosker G, Jarvis B (2002) Temozolomide. Am J Cancer 1(1):55-80
30. Diez B, Statkevich P, Zhu Y, Abutarif M, Xuan F, Kantesaria B, Cutler D, Cantillon M, Schwarz M, Pallotta M, Ottaviano F (2010) Evaluation of the exposure equivalence of oral versus intravenous temozolomide. Cancer Chemother Pharmacol 65(4):727-734
31. Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM (2007) Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Clin Cancer Res 13(14):4271-4279 (Pubitemid 47105992)
32. Cisternino S, Mercier C, Bourasset F, Fß Roux, Scherrmann J-M (2004) Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64(9):3296-3301. doi:10.1158/0008-5472. can-03-2033
33. Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, Houghton JA, Stewart CF, Houghton PJ (1997) Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 3(3):423-431 (Pubitemid 27158067)
34. J-i Kuroda, J-i Kuratsu, Yasunaga M, Koga Y, Kenmotsu H, Sugino T, Matsumura Y (2010) Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab. Clin Cancer Res 16(2):521-529
35. Bissery MC, Vrignaud P, Lavelle F, Chabot G (1996) Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7(4):437-460 (Pubitemid 26249198)
36. Bissery M-C, Vrignaud P, Lavelle F, Chabot G (1996) Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice. Ann N Y Acad Sci 803(1):173-180. doi:10.1111/j.1749-6632.1996.tb26386.x (Pubitemid 27057984)
37. Rouits E, Guichard S, Canal P, Chatelut E (2002) Non-linear pharmacokinetics of irinotecan in mice. Anticancer Drugs 13(6):631-635 (Pubitemid 34816458)
38. Hosokawa M (2008) Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13(2):412-431
39. Rivory LP, Bowles MR, Robert J, Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52(7):1103-1111 (Pubitemid 26338269)
40. Ghiasuddin SM, Soderlund DM (1984) Hydrolysis of pyrethroid insecticides by soluble mouse brain esterases. Toxicol Appl Pharmacol 74(3):390-396 (Pubitemid 14089577)
41. Smith NF, Figg WD, Sparreboom A (2006) Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20(2):163-175 (Pubitemid 43087700)
42. Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JHM, Beijnen JH, van Tellingen O (2013) Abcc4 together with Abcb1 and Abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clin Cancer Res 19(8):2084-2095
43. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96(4):1698-1705
44. Chen C, Hanson E, Watson JW, Lee JS (2003) P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31(3):312-318. doi:10.1124/dmd.31.3.312 (Pubitemid 36249686)
45. Kivistö K, Zukunft J, Hofmann U, Niemi M, Rekersbrink S, Schneider S, Luippold G, Schwab M, Eichelbaum M, Fromm M (2004) Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. Naunyn Schmiedebergs Arch Pharmacol 370(2):124-130 (Pubitemid 39222864)
46. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CECA, Kasman IN, LaPerle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/1b knockout mouse model. Drug Metab Dispos 33(1):165-174 (Pubitemid 40023528)